Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters

被引:18
|
作者
Bag, Asim K. [1 ]
Cezayirli, Phillip C. [2 ]
Davenport, Jake J. [1 ]
Gaddikeri, Santhosh [3 ]
Fathallah-Shaykh, Hassan M. [2 ]
Cantor, Alan [4 ]
Han, Xiaosi S. [2 ]
Nabors, Louis B. [2 ]
机构
[1] Univ Alabama Birmingham, Dept Radiol, Birmingham, AL 35249 USA
[2] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA
[3] Univ Washington, Dept Radiol, Seattle, WA 98195 USA
[4] Univ Alabama Birmingham, Dept Prevent Med, Birmingham, AL 35294 USA
关键词
Peritumoral rCBV and rCBF; Perfusion MRI; GBM; Glioblastoma; Overall survival; Progression free survival; CEREBRAL BLOOD-VOLUME; LOW-GRADE GLIOMAS; INTRACRANIAL MASS LESIONS; PROGNOSTIC VALUE; BRAIN-TUMORS; MR; PREDICT; DIFFERENTIATION; PERMEABILITY; PROGRESSION;
D O I
10.1007/s11060-014-1560-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The objective of this study was to evaluate if peritumoral (PT) perfusion parameters obtained from dynamic susceptibility weighted contrast enhanced perfusion MRI can predict overall survival (OS) and progression free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (GBM). Twenty-eight newly diagnosed GBM patients, who were treated with resection followed by concurrent chemoradiation and adjuvant chemotherapy, were included in this study. Evaluated perfusion parameters were pre- and post-treatment PT relative cerebral blood volume (rCBV) and relative cerebral blood flow (rCBF). Proportional hazard analysis was used to assess the relationship OS, PFS and perfusion parameters. Kaplan-Meier survival estimates and log-rank test were used to characterize and compare the patient groups with high and low perfusion parameter values in terms of OS and PFS. Pretreatment PT rCBV and rCBF were not associated with OS and PFS whereas there was statistically significant association of both posttreatment PT rCBV and rCBF with OS and posttreatment rCBV with PFS (association of PFS and posttreatment rCBF was not statistically significant). Neither the Kaplan-Meier survival estimates nor the log-rank test demonstrated any differences in OS between high and low pretreatment PT rCBV values and rCBF values; however, high and low post-treatment PT rCBV and rCBF values did demonstrate statistically significant difference in OS and PFS. Our study found posttreatment, not pretreatment, PT perfusion parameters can be used to predict OS and PFS in patients with newly diagnosed GBM.
引用
收藏
页码:361 / 370
页数:10
相关论文
共 17 条
  • [1] Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters
    Asim K. Bag
    Phillip C. Cezayirli
    Jake J. Davenport
    Santhosh Gaddikeri
    Hassan M. Fathallah-Shaykh
    Alan Cantor
    Xiaosi S. Han
    Louis B. Nabors
    Journal of Neuro-Oncology, 2014, 120 : 361 - 370
  • [2] Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging
    Li, Yan
    Lupo, Janine M.
    Parvataneni, Rupa
    Lamborn, Kathleen R.
    Cha, Soonmee
    Chang, Susan M.
    Nelson, Sarah J.
    NEURO-ONCOLOGY, 2013, 15 (05) : 607 - 617
  • [3] Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme
    Li, Yan
    Lupo, Janine M.
    Polley, Mei-Yin
    Crane, Jason C.
    Bian, Wei
    Cha, Soonmee
    Chang, Susan
    Nelson, Sarah J.
    NEURO-ONCOLOGY, 2011, 13 (05) : 546 - 557
  • [4] Pre- and Post-Treatment Imaging of Primary Central Nervous System Tumors in the Molecular and Genetic Era
    Ahn, Sung Soo
    Cha, Soonmee
    KOREAN JOURNAL OF RADIOLOGY, 2021, 22 (11) : 1858 - 1874
  • [5] Angiogenesis inhibitors effects on overall survival and progression-free survival in newly diagnosed primary glioblastoma multiforme: a meta-analysis of twelve randomized clinical trials
    Motamed-Sanaye, Ali
    Mortezaei, Ali
    Afshari, Amir R.
    Saadatian, Zahra
    Faraji, Amir H.
    Sheehan, Jason P.
    Mokhtari, Ali Mohammad
    JOURNAL OF NEURO-ONCOLOGY, 2025, 171 (02) : 313 - 328
  • [6] Post-treatment changes of tumour perfusion parameters can help to predict survival in patients with high-grade astrocytoma
    Sanz-Requena, Roberto
    Revert-Ventura, Antonio J.
    Garcia-Marti, Gracian
    Salame-Gamarra, Fares
    Perez-Girbes, Alexandre
    Molla-Olmos, Enrique
    Marti-Bonmati, Luis
    EUROPEAN RADIOLOGY, 2017, 27 (08) : 3392 - 3400
  • [7] Response assessment during chemoradiation using a hypercellular/hyperperfused imaging phenotype predicts survival in patients with newly diagnosed glioblastoma
    Kim, Michelle M.
    Aryal, Madhava P.
    Sun, Yilun
    Parmar, Hemant A.
    Li, Pin
    Schipper, Matthew
    Wahl, Daniel R.
    Lawrence, Theodore S.
    Cao, Yue
    NEURO-ONCOLOGY, 2021, 23 (09) : 1537 - 1546
  • [8] Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study
    Ardon, Hilko
    Van Gool, Stefaan
    Lopes, Isabel Spencer
    Maes, Wim
    Sciot, Raf
    Wilms, Guido
    Demaerel, Philippe
    Bijttebier, Patricia
    Claes, Laurence
    Goffin, Jan
    Van Calenbergh, Frank
    De Vleeschouwer, Steven
    JOURNAL OF NEURO-ONCOLOGY, 2010, 99 (02) : 261 - 272
  • [9] Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study
    Hilko Ardon
    Stefaan Van Gool
    Isabel Spencer Lopes
    Wim Maes
    Raf Sciot
    Guido Wilms
    Philippe Demaerel
    Patricia Bijttebier
    Laurence Claes
    Jan Goffin
    Frank Van Calenbergh
    Steven De Vleeschouwer
    Journal of Neuro-Oncology, 2010, 99 : 261 - 272
  • [10] Dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging parameters for predicting MGMT promoter methylation and prognostic value in newly diagnosed patients with glioblastoma
    Chida, Daiki
    Okita, Yoshiko
    Utsugi, Reina
    Kuroda, Hideki
    Hirayama, Ryuichi
    Kijima, Noriyuki
    Arisawa, Atsuko
    Kagawa, Naoki
    Kanemura, Yonehiro
    Yoshimura, Shinichi
    Tomiyama, Noriyuki
    Kishima, Haruhiko
    ONCOLOGY LETTERS, 2024, 28 (06)